@Theman in reply to your last post (sorry, somehow I am unable to post a direct "reply"):
Let me start of with another question:
When Mercedes failed the Elk Test back in 1997, did you as a result question any other Mercedes models, or BMW, Audi, Toyota, Mitsubishi given that they are also Motor Vehicles?
The news is definitely bad for Fate Therapeutics. As you mentioned, their pipeline has been pretty much wiped out:
https://fatetherapeutics.com/pipeline/
But despite that, they have a Market Capital of US$550 million.
In comparison, Chimeric Therapeutics:
https://chimerictherapeutics.com/our-pipeline/
Market Capital of A$25 million.
Fate's pipeline is based on a different technology entirely:
https://fatetherapeutics.com/science/ipsc-platform/
Whilst iPSC-technology comes with many advantages, downside is that due to most of these developments being "first-ever" therapies such as FT516 being "the first-ever cell therapy derived from a genetically engineered pluripotent stem cell cleared for clinical testing in the world" (https://www.clinicalleader.com/doc/fate-therapeutics-announces-patient-ipsc-cell-cancer-immunotherapy-assessment-0001), I would consider the risk of failure in a P1 trial being significantly higher. In this case Fate's approach of genetically engineering NK cells / CAR NK cells may have simply not worked out and further "tweaking" is required.
Even FT819 "first-ever, iPSC-derived CAR T-cell product candidate" had the following to report:
https://ashpublications.org/blood/article/140/Supplement%201/4577/490801/Interim-Phase-I-Clinical-Data-of-FT819-101-a-Study
In our case, we have clinical (CORE-) NK data that seems to suggest otherwise:
https://company-announcements.copyright link/asx/chm/8f597477-9da3-11ec-8d2b-62a0ebf3375e.pdfPersonally, I am looking forward to further clinical results of our pipeline and hopefully we get to a similar "crashed" FATE Market Capital soon.
(20min delay)